Stock listing
BOATS:PRME Prime Medicine, Inc. Stock
US listing (BOATS) of Prime Medicine, Inc. · home listing NASDAQ:PRME
Follow Prime Medicine, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PRME
$4.97 USD +0.42 (+9.2%)
Close on Nov 4, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PRME
- Day range
- $4.59 – $5.12 USDNov 4, 2026
- Volume
- 4.39M sharesNov 4, 2026
- Market cap
- $901.4M USDAt the close on Nov 4, 2026 · price × 181.4M shares outstanding
- 52-week range
- $2.67 – $5.91 USDLowest and highest trades, Nov 5, 2025 – Nov 4, 2026
- Traded on an average day
- $15.05M USDMedian day 3.31M shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PRME · Home | $4.97 USD | +0.42 (+9.2%) | 4,394,906 | $4.75 | $5.12 | $4.59 | $4.55 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:PRME · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.97 | +0.42 | +9.2% | $4.75 | $5.12 | $4.59 | 4,394,906 | |
| $4.55 | +0.11 | +2.5% | $4.50 | $4.885 | $4.435 | 4,115,219 | |
| $4.44 | -0.28 | -5.9% | $4.74 | $4.84 | $4.361 | 4,122,637 | |
| $4.72 | -0.52 | -9.9% | $5.03 | $5.20 | $4.675 | 6,556,079 | |
| $5.24 | -0.12 | -2.2% | $5.21 | $5.91 | $5.19 | 10,327,326 | |
| $5.36 | +1.01 | +23.2% | $4.245 | $5.43 | $4.11 | 15,165,766 | |
| $4.35 | +0.74 | +20.5% | $3.62 | $4.41 | $3.57 | 8,810,312 | |
| $3.61 | -0.06 | -1.6% | $3.66 | $3.70 | $3.57 | 2,508,756 | |
| $3.67 | -0.06 | -1.6% | $3.70 | $3.70 | $3.38 | 4,560,300 | |
| $3.73 | -0.08 | -2.1% | $3.68 | $3.92 | $3.62 | 4,657,500 | |
| $3.81 | -0.11 | -2.8% | $3.92 | $4.005 | $3.795 | 2,436,400 | |
| $3.92 | +0.09 | +2.3% | $3.75 | $4.05 | $3.73 | 3,694,600 | |
| $3.83 | +0.36 | +10.4% | $3.56 | $3.87 | $3.49 | 4,250,500 | |
| $3.47 | -0.14 | -3.9% | $3.55 | $3.605 | $3.41 | 4,386,000 | |
| $3.61 | +0.48 | +15.3% | $3.12 | $3.65 | $3.06 | 6,299,900 | |
| $3.13 | -0.19 | -5.7% | $3.21 | $3.22 | $3.045 | 4,236,500 | |
| $3.32 | -0.29 | -8.0% | $3.61 | $3.61 | $3.27 | 4,058,100 | |
| $3.61 | -0.38 | -9.5% | $3.95 | $3.965 | $3.58 | 3,132,900 | |
| $3.99 | +0.41 | +11.5% | $3.57 | $4.14 | $3.54 | 8,064,200 | |
| $3.58 | -0.32 | -8.2% | $3.83 | $3.898 | $3.52 | 7,721,200 | |
| $3.90 | +0.40 | +11.4% | $3.36 | $4.02 | $3.30 | 11,194,100 | |
| $3.50 | +0.29 | +9.0% | $3.56 | $3.718 | $3.26 | 12,014,000 | |
| $3.21 | +0.23 | +7.7% | $3.00 | $3.26 | $2.88 | 4,716,900 | |
| $2.98 | -0.01 | -0.3% | $3.05 | $3.075 | $2.92 | 2,108,600 | |
| $2.99 | -0.065 | -2.1% | $3.05 | $3.105 | $2.98 | 2,825,800 | |
| $3.055 | -0.035 | -1.1% | $3.11 | $3.19 | $3.02 | 3,126,900 | |
| $3.09 | +0.215 | +7.5% | $2.93 | $3.135 | $2.88 | 3,605,600 | |
| $2.875 | -0.025 | -0.9% | $2.85 | $2.92 | $2.77 | 3,681,400 | |
| $2.90 | -0.17 | -5.5% | $3.42 | $3.44 | $2.875 | 7,116,300 | |
| $3.07 | -0.06 | -1.9% | $3.11 | $3.13 | $2.99 | 4,485,400 | |
| $3.13 | -0.41 | -11.6% | $3.53 | $3.53 | $3.12 | 3,331,900 | |
| $3.54 | +0.35 | +11.0% | $3.22 | $3.565 | $3.20 | 2,717,700 | |
| $3.19 | +0.07 | +2.2% | $3.19 | $3.27 | $3.10 | 2,946,300 | |
| $3.12 | -0.02 | -0.6% | $3.13 | $3.17 | $3.045 | 4,672,500 | |
| $3.14 | +0.14 | +4.7% | $3.11 | $3.39 | $3.10 | 3,252,700 | |
| $3.00 | -0.14 | -4.5% | $3.18 | $3.22 | $2.93 | 3,290,400 | |
| $3.14 | -0.04 | -1.3% | $3.18 | $3.22 | $3.00 | 2,573,100 | |
| $3.18 | +0.05 | +1.6% | $3.10 | $3.28 | $3.10 | 1,616,200 | |
| $3.13 | -0.22 | -6.6% | $3.38 | $3.44 | $3.10 | 3,075,700 | |
| $3.35 | -0.12 | -3.5% | $3.37 | $3.42 | $3.31 | 2,386,300 | |
| $3.47 | -0.09 | -2.5% | $3.47 | $3.535 | $3.29 | 4,223,300 | |
| $3.56 | -0.14 | -3.8% | $3.65 | $3.65 | $3.41 | 3,600,800 | |
| $3.70 | -0.01 | -0.3% | $3.83 | $3.86 | $3.65 | 1,618,700 | |
| $3.71 | +0.04 | +1.1% | $3.70 | $3.72 | $3.49 | 2,311,700 | |
| $3.67 | +0.10 | +2.8% | $3.50 | $3.705 | $3.47 | 2,473,900 | |
| $3.57 | -0.02 | -0.6% | $3.54 | $3.71 | $3.48 | 2,453,000 | |
| $3.59 | -0.02 | -0.6% | $3.54 | $3.635 | $3.46 | 2,092,600 | |
| $3.61 | -0.03 | -0.8% | $3.57 | $3.70 | $3.48 | 2,693,500 | |
| $3.64 | +0.06 | +1.7% | $3.55 | $3.665 | $3.48 | 1,832,800 | |
| $3.58 | -0.13 | -3.5% | $3.66 | $3.66 | $3.435 | 1,950,200 | |
| $3.71 | +0.46 | +14.2% | $3.30 | $3.71 | $3.285 | 3,320,951 | |
| $3.25 | -0.14 | -4.1% | $3.38 | $3.40 | $3.195 | 2,267,579 | |
| $3.39 | +0.15 | +4.6% | $3.26 | $3.49 | $3.24 | 3,597,000 | |
| $3.24 | -0.30 | -8.5% | $3.43 | $3.50 | $3.20 | 3,797,900 | |
| $3.54 | +0.49 | +16.1% | $3.29 | $3.59 | $3.25 | 6,791,300 | |
| $3.05 | -0.12 | -3.8% | $3.10 | $3.199 | $3.02 | 1,271,000 | |
| $3.17 | +0.08 | +2.6% | $3.07 | $3.19 | $3.021 | 1,500,700 | |
| $3.09 | -0.08 | -2.5% | $3.14 | $3.14 | $3.00 | 1,571,000 | |
| $3.17 | -0.03 | -0.9% | $3.23 | $3.285 | $3.13 | 1,888,700 | |
| $3.20 | -0.06 | -1.8% | $3.24 | $3.305 | $3.17 | 1,444,200 | |
| $3.26 | +0.11 | +3.5% | $3.20 | $3.29 | $3.085 | 2,258,000 | |
| $3.15 | +0.07 | +2.3% | $3.09 | $3.315 | $3.06 | 3,595,800 | |
| $3.08 | +0.13 | +4.4% | $3.00 | $3.12 | $2.97 | 1,976,900 | |
| $2.95 | -0.13 | -4.2% | $3.06 | $3.15 | $2.91 | 2,554,600 | |
| $3.08 | +0.10 | +3.4% | $2.98 | $3.12 | $2.89 | 3,145,000 | |
| $2.98 | +0.17 | +6.0% | $2.875 | $2.98 | $2.82 | 3,161,500 |
- Ticker
- BOATS:PRME
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 5, 2026
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 44 slides
Latest news
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Oct 5, 2026
Closed $3.21 (+7.7%) on Oct 5, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Sep 24, 2026
Closed $2.90 (-5.5%) on Sep 25, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 6, 2026
Closed $2.95 (-4.2%) on Aug 6, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Jul 23, 2026
Closed $2.95 (-0.7%) on Jul 24, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Jul 8, 2026
Closed $4.62 (+15.8%) on Jul 8, 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Jun 22, 2026
Closed $3.37 (+4.3%) on Jun 22, 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Jun 18, 2026
Closed $3.23 (+2.2%) on Jun 18, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
Closed $3.14 (-2.2%) on Jun 3, 2026
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Closed $3.12 (-8.7%) on May 7, 2026
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Apr 16, 2026
Closed $3.67 (-3.2%) on Apr 16, 2026
Decks
Investor Presentation (October 2026)
Investor deck · 44 slides · October 2026
Investor Presentation (March 2026)
Investor deck · 41 slides · Mar 3, 2026
Investor Presentation (January 2026)
Investor deck · 41 slides · Jan 12, 2026
Technical Presentation (November 2025)
Technical · 27 slides · Nov 12, 2025
Prime Medicine, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 34 in all · newest Oct 5, 2026 · oldest 2024
- Decks
- 18 decks · latest October 2026
Where Prime Medicine, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PRME · Home listing | NASDAQ | United States | USD |
| BOATS:PRME · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Prime Medicine, Inc.